Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment

Core Insights - Kali Therapeutics has signed a licensing agreement with Sanofi to develop an experimental treatment for autoimmune diseases, specifically KT501 [1][2] Group 1: Licensing Agreement Details - Sanofi will acquire global rights to KT501, a tri-specific antibody developed using Kali Therapeutics' proprietary platform [2] - Kali Therapeutics will receive $180 million in upfront and near-term payments, with potential for up to $1.05 billion in development and commercial milestone payments [2] - The agreement includes tiered royalties on product sales, ranging from high-single digits to double digits if the drug is approved [2] Group 2: Drug Development and Testing - KT501 is currently undergoing early-stage testing in rheumatoid arthritis patients to evaluate its safety and tolerability [3] - Preclinical studies in non-human primates indicated that KT501 significantly reduced B cells while minimizing adverse immune reactions associated with similar treatments [3][4] - The drug is designed to target and modulate immune cells involved in autoimmune disorders, including lupus and rheumatoid arthritis [4] Group 3: Sanofi's Existing Portfolio - Sanofi markets Kevzara, an approved rheumatoid arthritis treatment developed in collaboration with Regeneron Pharmaceuticals, and is also advancing new anti-inflammatory candidates [4]